Premise, promise and challenges of MDMA assisted therapy for PTSD
Santiago Madero, O. D. Alvarez
European Neuropsychopharmacology February 15, 2023 DOI: 10.1016/j.euroneuro.2023.02.002 (opens in new tab)
Study at a glance
AI-extracted from the abstractAbstract
COVID-19
Citations in the library
Cited by 13
- MDMA-Based Psychotherapy in Treatment-Resistant Post-Traumatic Stress Disorder (PTSD): A Brief Narrative Overview of Current Evidence Diseases November 3, 2023
- Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis. European Neuropsychopharmacology November 7, 2025
- What should constitute a control condition in psychedelic drug trials? Nature Mental Health October 1, 2024
- Moving psychedelic-assisted therapies from promising research into routine clinical practice: Lessons from the field of implementation science Translational Behavioral Medicine October 17, 2024
- Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning‐Based Advanced Perspectives Advanced Science March 20, 2025
and 8 more in the library
Cites 7
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- Preparing for the Bursting of the Psychedelic Hype Bubble. JAMA Psychiatry October 1, 2022
- A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy Frontiers in Psychiatry March 20, 2019
- A century of research on psychedelics: A scientometric analysis on trends and knowledge maps of hallucinogens, entactogens, entheogens and dissociative drugs. European Neuropsychopharmacology November 1, 2022
- The Costs and Health Benefits of Expanded Access to MDMA-assisted Therapy for Chronic and Severe PTSD in the USA: A Modeling Study Clinical drug investigation March 1, 2022
and 2 more in the library